Hospira Acquires Sculptor
30 Abril 2008 - 12:53PM
PR Newswire (US)
- Acquisition Provides Bar Code Point-of-Care Technology to Enhance
Patient Safety and Clinician Workflow Capabilities - LAKE FOREST,
Ill., April 30 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE:HSP),
a global specialty pharmaceutical and medication delivery company,
and St. Clair Health Corporation, today announced that Hospira has
acquired Sculptor Developmental Technologies, a subsidiary of St.
Clair Health Corporation. Sculptor is a leading software
engineering company formed by St. Clair Hospital in 1993 to advance
the use of technology to improve patient care. As part of a related
arrangement, St. Clair Hospital will serve as a development and
test site for Hospira medication management products. "Acquiring
Sculptor expands Hospira's ability to offer device and software
solutions that enhance safety and productivity," said Chris Kolber,
president, Global Devices, Hospira. "Their approach to developing
products designed by clinicians, for clinicians, results in high
adoption rates and an immediate impact to patient safety and
clinician efficiency." Sculptor developed VeriScan Rx, a software
application that supports bar code medication administration at the
point of care. It is designed to streamline the medication
administration process to enhance patient safety and clinician
workflow. According to the Institute of Medicine (IOM), medication
errors impact 1.5 million people in the United States per year. Bar
code enabled systems are becoming increasingly important to
addressing medication errors by verifying the "five rights" of
medication administration: right medication, right dose, right
patient, right time and right route of administration. "This
acquisition brings together two leaders in healthcare IT -- Hospira
has led the industry in barcoding medications and infusion
technology; and St. Clair, through Sculptor, was the first hospital
in the country to combine barcoding and RFID in a single mobile
device for the real-time workflow needs of clinical staff," said
Richard Schaeffer, vice president and chief information officer,
St. Clair Hospital. The acquisition of Sculptor supports Hospira's
approach of interfacing its products with other technologies to
meet the evolving needs of hospitals. Hospira currently partners
with several leading hospital information system providers to
establish communications between their applications and its own.
These companies include Cerner Corp., McKesson Corporation and
Siemens Medical Solutions. Financial details of the Sculptor
agreement were not disclosed. About Sculptor Developmental
Technologies, Inc. Sculptor Developmental Technologies, Inc. was
established in 1993 as a software engineering company dedicated to
providing software solutions for healthcare. With the advent of
VeriScan in 2003, Sculptor remains focused on bedside patient
safety initiatives. Currently there are more than 125 hospitals in
the United States, Canada and Europe using Sculptor's applications.
About St. Clair Hospital St. Clair Hospital is a leading acute care
hospital serving the approximately 400,000 residents of the South
Hills of Pittsburgh with a comprehensive array of inpatient and
outpatient services. The Hospital regularly receives state and
national recognition for clinical excellence, patient safety, and
information technology, including the 2007 Leadership Award for
Clinical Excellence from VHA, and distinction as a best practice
facility from the Institute for Healthcare Improvement (IHI) for
medication reconciliation. St. Clair is among Pennsylvania's
highest achieving hospitals in patient safety initiatives and
clinical best practices, and is the only Pittsburgh-area hospital
to be named one of the 100 Best Places to Work in Pennsylvania for
six consecutive years. About Hospira Hospira, Inc. is a global
specialty pharmaceutical and medication delivery company dedicated
to Advancing Wellness(TM). As the world leader in specialty generic
injectable pharmaceuticals, Hospira offers one of the broadest
portfolios of generic acute-care and oncology injectables, as well
as integrated infusion therapy and medication management solutions.
Through its products, Hospira helps improve the safety, cost and
productivity of patient care. The company is headquartered in Lake
Forest, Ill., and has more than 14,000 employees. Learn more at
http://www.hospira.com/. Private Securities Litigation Reform Act
of 1995 -- A Caution Concerning Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Hospira cautions that these forward-looking statements are subject
to risks and uncertainties that may cause actual results to differ
materially from those indicated in the forward-looking statements.
Economic, competitive, governmental, technological and other
factors that may affect Hospira's operations and may cause actual
results to be materially different from expectations include the
risks and uncertainties set forth under the headings "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition
and Results of Operations" in Hospira's latest Annual Report on
Form 10-K filed with the Securities and Exchange Commission, which
is incorporated by reference. Hospira undertakes no obligation to
release publicly any revisions to forward-looking statements as the
result of subsequent events or developments.
http://www.newscom.com/cgi-bin/prnh/20040503/HSPLOGO
http://photoarchive.ap.org/ DATASOURCE: Hospira, Inc. CONTACT:
media, Tareta Adams of Hospira, Inc., +1-224-212-2535; or Andrea
Kalina of St. Clair Hospital, +1-412-942-4000; or investors, Lynn
McHugh of Hospira, Inc., +1-224-212-2363 Web site:
http://www.hospira.com/
Copyright
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024